Logo

Allarity Signs a License Agreement with Oncoheroes Biosciences to Advance Dovitinib and Stenoparib for Pediatric Cancer

Share this

Allarity Signs a License Agreement with Oncoheroes Biosciences to Advance Dovitinib and Stenoparib for Pediatric Cancer

Shots:

  • Allarity to receive an up front license fee & regulatory milestones for each program while Oncoheroes will receive commercialization rights based on Allarity’s 1st buy-back option. If Allarity does not exercise the buy-back option, it will eligible for clinical/regulatory milestones along with royalties on sales of stenoparib & dovitinib.
  •  Oncoheroes obtains an exclusive right globally to fund & conduct clinical development of both products in pediatric cancers. Allarity will support Oncoheroes’ pediatric trials by providing access to its DRP companion diagnostic for patients selection
  • Allarity has submitted an NDA to the US FDA for dovitinib in RCC along with Dovitinib-DRP companion diagnostic

Ref: Allarity | Image: Linkedin

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions